About usThe EyeSense company
Since 2006, EyeSense has been synonymous with innovation and advancement in medical technology. As a spin-off from CIBA Vision (Alcon), formerly part of the Novartis Group, we build on a strong foundation of experience and expertise. Our primary focus is developing an innovative continuous glucose monitoring system, crafted with precision and care to simplify daily life for people with chronic conditions.
Our way
Our journey started in 2007 with initial concept studies that laid the groundwork for our current developments. Since then, we’ve consistently advanced our system with a forward-looking approach. Sustainability remains central to our mission: extended wear time and reusable components make our system an environmentally friendly choice. Join us as we take EyeSense into the future—become part of our vision.
Our vision
Our long-term vision is to become the leader in innovative, comprehensive biological detection methods using photometrically measurable biomarkers. We are starting by introducing an additional therapy option for diabetics, while our ongoing development focuses on protecting health and sustainably improving quality of life.
Our team
EyeSense is driven by an experienced team dedicated to shaping the future of medical technology with passion and expertise. Together, we strive to make EyeSense a trusted partner for both our users and investors, firmly believing that the best solutions arise where experience meets innovation.
Michael Tillmann
serves as the Executive Chairman of EyeSense AG and is a strategic investor through his company, Amatar Group. Before this, he spent over eight years at Roche Diagnostics, where he held the positions of CEO for both the Asia Pacific and North America regions and was a member of the Roche Global Executive Board. In these roles, he managed the Diagnostics Division, which included overseeing the Diabetes business. Mr. Tillmann also holds positions on the supervisory boards of multiple private and publicly listed companies and acts as an advisor to both industry and government entities.
Dario Clos
Chief Operating Officer (COO) of EyeSense AG and Managing Director of EyeSense GmbH, oversees the operational activities of the German subsidiary. A qualified industrial engineer with extensive experience in the pharmaceutical and medical technology sectors, Dario brings invaluable expertise to the EyeSense project, focusing on its successful implementation and transition to industrial scale. With +15 years in the diabetes market, he specializes in the industrialization of diabetes treatments, driving innovation and efficiency in delivering transformative therapies to market.
Thomas Möller
is currently serving as the CFO of EyeSense AG and represents BioMedInvest as one of its founding investors. He has extensive experience in both start-up companies within the life sciences sector and large multinational organizations. Since 2001, he has been active in the venture community as an Investment Manager, specializing in medical device companies. Throughout his career, he has held positions on various boards across Europe. Before his venture work, he was a Senior Manager with PricewaterhouseCoopers, working in both Europe and the United States.
Mr. Möller earned his Swiss Certified Public Accountant qualification in 1996 and holds a master’s degree in Economics and Business Administration from the University of Basel, completed in 1991.
Dr. Achim Müller
Chief Technology Officer (CTO) of EyeSense AG and Managing Director of EyeSense GmbH, is the founder and visionary behind FiberSense technology. With over 25 years of experience in medical product research and development, Dr. Müller is recognized as one of the industry’s leading experts. His work is fueled by a commitment to guide innovative products from conception to market readiness, with the goal of expanding treatment options for patients globally.
Dr. Bhuwnesh Agrawal
Chief Medical Officer of EyeSense AG, +40 years of experience in the healthcare industry including clinical and commercial experience. Prior served in companies including Roche (including Diabetes), Eppendorf and Sysmex C suite manager/ CEO. As a medical doctor and industry expert, BA has the know-how to develop the product to conduct the clinical studies for approval and generate data for marketing and sales.
Susanne Olpeter
Business Manager and first point of contact of EyeSense GmbH. She has been with EyeSense since 2011 and is Head of Business Administration. In her more than 30 years of professional experience in the healthcare industry, Ms. Olpeter has held various positions in the areas of Sales & Marketing and Corporate Management. Due to the international orientation of her activities and several years abroad, Ms. Olpeter has a broad international and multicultural competence.
Get to know us and our vision
Be the first to experience our innovative solution! Sign up now for updates and stay informed on availability.